- Home
- BCG vs LVTX Comparison
BCG vs LVTX Comparison
Compare BCG & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- LVTX
- Stock Information
- Founded
- BCG 2016
- LVTX 2016
- Country
- BCG United States
- LVTX Netherlands
- Employees
- BCG N/A
- LVTX N/A
- Industry
- BCG
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- LVTX Health Care
- Exchange
- BCG Nasdaq
- LVTX Nasdaq
- Market Cap
- BCG 45.6M
- LVTX 42.1M
- IPO Year
- BCG N/A
- LVTX 2021
- Fundamental
- Price
- BCG $2.58
- LVTX $1.01
- Analyst Decision
- BCG
- LVTX Buy
- Analyst Count
- BCG 0
- LVTX 3
- Target Price
- BCG N/A
- LVTX $4.67
- AVG Volume (30 Days)
- BCG 76.8K
- LVTX 153.9K
- Earning Date
- BCG 11-14-2024
- LVTX 12-10-2024
- Dividend Yield
- BCG N/A
- LVTX N/A
- EPS Growth
- BCG N/A
- LVTX N/A
- EPS
- BCG N/A
- LVTX N/A
- Revenue
- BCG $161,721,000.00
- LVTX $7,345,000.00
- Revenue This Year
- BCG N/A
- LVTX N/A
- Revenue Next Year
- BCG N/A
- LVTX N/A
- P/E Ratio
- BCG N/A
- LVTX N/A
- Revenue Growth
- BCG N/A
- LVTX N/A
- 52 Week Low
- BCG $1.85
- LVTX $1.00
- 52 Week High
- BCG $16.61
- LVTX $6.47
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- LVTX 32.32
- Support Level
- BCG N/A
- LVTX $1.00
- Resistance Level
- BCG N/A
- LVTX $1.95
- Average True Range (ATR)
- BCG 0.00
- LVTX 0.17
- MACD
- BCG 0.00
- LVTX -0.06
- Stochastic Oscillator
- BCG 0.00
- LVTX 6.00
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.